Skip to content

A randomized controlled trial on the promotion of rapid recovery after ovarian cystectomy via transvaginal natural orifice transluminal endoscopic surgery by auricular point pressure seed and press needle therapy

A randomized controlled trial on the promotion of rapid recovery after ovarian cystectomy via transvaginal natural orifice transluminal endoscopic surgery by auricular point pressure seed and press needle therapy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025001465
Enrollment
Unknown
Registered
2025-07-21
Start date
2025-06-29
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign ovarian tumor

Interventions

Trial group:Under routine care combined traditional Chinese medicine treatment of auricular point pressing and pressing acupuncture was carried out
Control group:Carry out routine care, including psychological guidance, eating guidance, and guidance on getting out of bed for exercise, etc

Sponsors

Chengdu Women and Children's Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1)Female aged 18 to 55. 2) Patients diagnosed with ovarian cysts through imaging examinations (such as ultrasound CT etc.) and requiring transvaginal natural cavity endoscopic surgery (vNOTES) removal. 3) Meet the indications for vNOTES surgery including but not limited to the size and location of the cyst and the general condition of the patient meeting the surgical requirements. 4) Be able to cooperate in completing the visits and related inspections stipulated in the plan. ' 5) The subjects voluntarily participate in the clinical trial and agree or have their guardians agree to sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1) Those who undergo other major surgical treatments within 3 months before enrollment and are scheduled to do so during the trial or who are unable to recover from the side effects of any such surgery. 2) Patients with severe mental disorders such as schizophrenia depression etc. 3) Those with positive antibodies against the immunodeficiency virus (HIV); Those with positive hepatitis C virus (HCV) antibodies; Positive for Treponema pallidum antibody; Patients with active pulmonary tuberculosis who have been judged by researchers to have a relatively high risk of infection. 4) Those who suffer from severe systemic diseases and are determined by researchers to be unsuitable for surgical treatment. 5) People who have been using anticoagulant or antiplatelet drugs for a long time as well as patients with hematopoietic dysfunction or coagulation dysfunction. 6) Those who have participated in other interventional clinical trials within the three months prior to the screening.

Design outcomes

Primary

MeasureTime frame
The time of the first postoperative exhaust;

Secondary

MeasureTime frame
Hospitalization days;Complications during surgery;Complications during surgery;Postoperative intake of painkillers;The time of the first ambulation after the operation;The situation of the first defecation after the operation;patient satisfaction;Postoperative pain score;

Countries

China

Contacts

Public ContactHe Li

Chengdu Women's and Children's Central Hospital

helisc@163.com+86 138 8178 2966

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026